Herceptin-directed nanoparticles activated by an alternating magnetic field selectively kill HER-2 positive human breast cells in vitro via hyperthermia

International Journal of Hyperthermia

Volumn 27, Issue 7, 2011, Pages 682-697

  Zhang, Jianping ^a   Dewilde, Abiche H ^a   Chinn, Paul ^b   Foreman, Allan ^b   Barry, Stephen ^c   Kanne, David ^a   Braunhut, Susan J ^a  

^a UNIVERSITY OF MASSACHUSETTS LOWELL   (United States)

^b Aduro BioTech Inc   (United States)

^c Aspen MediSys   (United States)

Author keywords

Alternating magnetic field; HER 2; Herceptin; Hyperthermia; Nanoparticles

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; NANOPARTICLE; TRASTUZUMAB;

ALTERNATING MAGNETIC FIELD; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DRUG UPTAKE; HEAT; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; MAGNETIC FIELD;

ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FERRIC COMPOUNDS; HUMANS; HYPERTHERMIA, INDUCED; MAGNETIC FIELDS; NANOPARTICLES; RECEPTOR, ERBB-2;

EID: 80054061021     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656736.2011.609863     Document Type: Article

References (44)

1. Park JW, Neve RM, Szollosi J, Benz CC. Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer 2008;8:392-401.
2. Mukai H. Treatment strategy for HER2-positive breast cancer. Int J Clin Oncol 2010;15:335-340.
3. Mannocci A, De Feo E, de Waure C, Specchia ML, Gualano MR, Barone C, Ricciardi W, La Torre G. Use of trastuzumab in HER2-positive metastatic breast cancer beyond disease progression: A systematic review of published studies. Tumori 2010;96:385-391.
4. Capala J, Bouchelouche K. Molecular imaging of HER2- positive breast cancer: A step toward an individualized 'image and treat' strategy. Curr Opin Oncol 2010;22:559-566.
5. Smith TA. Towards detecting the HER-2 receptor and metabolic changes induced by HER-2-targeted therapies using medical imaging. Br J Radiol 2010;83:638-644.
6. Wuang SC, Neoh KG, Kang E, Pack DW, Leckband D. HER-2-mediated endocytosis of magnetic nanospheres and the implications in cell targeting and particle magnetization. Biomaterials 2009;29:2270-2279.
7. Kikumori T, Kobayashi T, Sawaki M, Imai T. Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes. Breast Cancer Res Treat 2009;113:435-441.
8. Gilchrist RK, Medal R, Shorrey WD, Hanselman RC, Parrott JC, Taylor CB. Selective inductive heating of lymph nodes. Ann Surg 1957;146:596-606.
9. Lacroix LM, Ho D, Sun S. Magnetic nanoparticles as both imaging probes and therapeutic agents. Curr Top Med Chem 2010;10:1184-1197.
10. Santra S, Kaittanis C, Grimm J, Perez JM. Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small 2009;5:1862-1868.
11. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: Targeted drug delivery for cancer. Curr Opin Chem Biol 2010;14:529-537.
12. Hu JCM, Zhang L. Therapeutic nanoparticles to combat cancer drug resistance. Current Drug Metabolism 2009;10:836-841.
13. Mohs AM, Provenzale JM. Applications of nanotechnology to imaging and therapy of brain tumors. Neuroimaging Clin N Am 2010;20:283-292.
14. Krishnan S, Diagaradjane P, Cho SH. Nanoparticle-mediated thermal therapy: Evolving strategies for prostate cancer therapy. Int J Hyperthermia 2010;26:775-789.
15. Hilger I, Hergt R, Kaiser WA. Use of magnetic nanoparticle heating in the treatment of breast cancer. IEE Proc Nanobiotechnol 2005;152:33-39. (Pubitemid 40453794)
16. DeNardo S, DeNardo G, Natarajan A, Miers L, Foreman A, Gruettner C, Adamson G, Ivkov R. Thermal dosimetry predictive of efficacy of 111 in-ChL6 nanoparticle AMFinduced thermoablative therapy for human breast cancer in mice. J Nucl Med 2007;48:437-444. (Pubitemid 47604930)
17. Ivkov R, DeNardo S, Daum W, Foreman A, Goldstein R, Nemkov V, DeNardo G. Application of high amplitude alternating magnetic fields for heat induction of nanoparticles localized in cancer. Clin Cancer Res 2005;11:7093-7103.
18. Lehmann J, Natarajan A, Denardo GL, Ivkov R, Foreman AR, Catapano C, Mirick G, Quang T, Gruettner C, Denardo SJ. Nanoparticle thermotherapy and external beam radiation therapy for human prostate cancer cells. Cancer Biother Radiopharm 2008;23:265-271. (Pubitemid 351630182)
19. Dennis CL, Jackson AJ, Borchers JA, Hoopes PJ, Strawbridge R, Foreman AR, van Lierop J, Grüttner C, Ivkov R. Nearly complete regression of tumors via collective behavior of magnetic nanoparticles in hyperthermia. Nanotechnology 2009;20:395103, doi: 10.1088/0957-4484/ 20/39/395103.
20. Grüttner C, Müller K, Teller J, Westphal F, Foreman A, Ivkov R. Synthesis and antibody conjugation of magnetic nanoparticles with improved specific power absorption rates for alternating magnetic field cancer therapy. J Magn Magn Mat 2007;311:181-186. (Pubitemid 46401005)
21. Natarajan A, Gruettner C, Ivkov R, DeNardo GL, Mirick G, Yuan A, Foreman A, DeNardo SJ. NanoFerrite particle based radioimmunonanoparticles: Binding affinity and in vivo pharmacokinetics. Bioconjug Chem 2008;19:1211-1218. (Pubitemid 351874943)
22. Kelm MA, Hammerstone JF, Schmitz HH. Identification and quantitation of flavanols and proanthocyanidins in foods: How good are the data? Clin Dev Imm 2005;12:35-41. (Pubitemid 41647028)
23. Wang G, Dewilde AH, Zhang J, Pal A, Vashist M, Bello D, Marx KA, Braunhut SJ, Therrien JM. A living cell quartz crystal microbalance biosensor for continuous monitoring of cytotoxic responses of macrophages to single-walled carbon nanotubes. Part Fibre Toxicol 2011;8:4.
24. Vorotnikova E, Rosenthal RA, Tries M, Doctrow SR, Braunhut SJ. Novel synthetic SOD/catalase mimetics can mitigate capillary endothelial cell apoptosis caused by ionizing radiation. Radiat Res 2010;173:748-759.
25. Vorotnikova E, Ivkov R, Foreman A, Tries M, Braunhut SJ. The magnitude and time-dependence of the apoptotic response of normal and malignant cells subjected to ionizing radiation versus hyperthermia. Int J Radiat Biol 2006;82:549-559. (Pubitemid 44373572)
26. Braunhut SJ, McIntosh D, Vorotnikova E, Zhou T, Marx KA. Detection of apoptosis and drug resistance of human breast cancer cells to taxane treatments using quartz crystal microbalance biosensor technology. Assay Drug Dev Technol 2005;3:77-88. (Pubitemid 40533255)
27. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: A pooled analysis of two randomized trials. Anticancer Drugs 2011;22:128-135.
28. Guarneri V, Barbieri E, Dieci MV, Piacentini F, Conte P. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat Rev 2010;36:62-66.
29. Saxena R, Dwivedi A. ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective. Med Res Rev 2010; DOI: 10.1002/ med.20209.
30. Chu PY, Li TK, Ding ST, Lai IR, Shen TL. EGF-induced Grb7 recruits and promotes Ras activity essential for the tumorigenicity of Sk-Br3 breast cancer cells. J Biol Chem 2010;285:29279-29285.
31. Carver JR. Management of trastuzumab-related cardiac dysfunction. Prog Cardiovasc Dis 2010;53:130-139.
32. Metzger Filho O, Saini KS, Azim Jr HA, Awada A. Prevention and management of major side effects of targeted agents in breast cancer. Crit Rev Oncol Hematol 2011; Sep 1. [Epub].
33. Schlorf T, Meincke M, Kossel E, Glüer C, Jansen O, Mentlein R. Biological properties of iron oxide nanoparticles for cellular and molecular magnetic resonance imaging. Int J Mol Sci 2011;12:12-23.
34. Tookman L, Roylance R. New drugs for breast cancer. Br Med Bull 2010;96:111-129.
35. Roti-Roti JL. Cellular responses to hyperthermia (40-46°C): Cell killing and molecular events. Int J Hyperthermia 2008;24:3-15.
36. AdraäW, d'Ambly CG, Hergt R, Hilger I, Kaiser WA. Temperature distribution as function of time around a small spherical heat source of local magnetic hyperthermia. J Magn Magn Mat 1999;194:197-203.
37. Kalambur VS, Longmire EK, Bischof JC. Cellular level loading and heating of superparamagnetic iron oxide nanoparticles. Langmuir 2007;23:12329-12336. (Pubitemid 350197410)
38. Rabin Y. Is intracellular hyperthermia superior to extracellular hyperthermia in the thermal sense? Int J Hyperthermia 2002;18:194-202. (Pubitemid 34618578)
39. Vauthier C, Tsapis N, Couvreur P. Nanoparticles: Heating tumors to death? Nanomedicine (Lond) 2011;6:99-109.
40. Yonezawa M, Otsuka T, Matsui N, Tsuji H, Kato KH, Moriyama A, Kato T. Hyperthermia induces apoptosis in malignant fibrous histiocytoma cells in vitro. Int J Cancer 1996;66:347-351. (Pubitemid 26163608)
41. Dewhirst MW, Prosnitz L, Thrall D, Prescott D, Clegg S, Charles C, MacFall J, Rosner G, Samulski T, Gillette E, et al. Hyperthermic treatment of malignant diseases: Current status and a view toward the future. Sem Oncol 1997;24:616-625. (Pubitemid 28035878)
42. Löblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S, Frejd FY. Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010;584:2670-2680.
43. Ahlgren S, Orlova A, Wållberg H, Hansson M, SandströM, Lewsley R, Wennborg A, Abrahmsé L, Tolmachev V, Feldwisch J. Targeting of HER2-expressing tumours using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med 2010;51:1131-1138.
44. Barry SE. Challenges in the development of magnetic particles for therapeutic applications. Int J Hyperthermia 2008;24:451-466.